Carasent sells cloud software to Nordic hospitals and clinics, including its CaraCloud platform for medical record access, referral handling and clinical workflows, and it is growing revenue at 31.6% with an 83.4% gross margin, which points to a subscription model that scales well. The defensible position comes from being embedded in clinical workflows where switching costs are high and procurement runs through public health systems on multi-year contracts. Operating margin of 8.4% is thin, and ROE of 4.8% shows the earnings base is still small, so the investment case rests on operating leverage as revenue compounds. At a trailing P/E of 47.3 with no forward estimate available, the stock is priced for that margin expansion to arrive, which makes margin progression the first thing to verify in the filings. With a market cap of 1.8B SEK and no index membership, the name is small enough that liquidity and coverage gaps are worth checking before any position sizing.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | kr 26.00 | first publication | kr 26.95 |
| 22 Oct 2026, 12:04 CEST | Rating | Overvalued | first publication | kr 27.50 |
| 22 Oct 2026, 12:04 CEST | Fair value | kr 14.64 | first publication | kr 27.50 |
Answered from Carasent AB (publ) fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| CARA.ST Carasent AB (publ) | kr 27.00 | kr 15 | 84% above | 45.8x | 4.8% | 66 | 58 |
| OPRX OptimizeRx Corporation Common Stock | $9.15 | $9 | 3% below | 38.1x | 3.7% | 54 | 51 |
| SY So-Young International Inc. American Depository Shares | $2.11 | - | - | - | -15.0% | 43 | 48 |
| ALCGM.PA Cegedim SA | €10.00 | €24 | 59% below | 10.5x | 4.3% | 51 | 58 |
| SPOK Spok Holdings Inc. Common Stock | $10.30 | $12 | 17% below | 18.8x | 8.4% | 75 | 48 |
| ASCN.SW Ascom Holding AG | CHF 5.72 | CHF 7 | 20% below | 11.0x | 25.7% | 78 | 73 |
| AMWL American Well Corporation Class A Common Stock | $13.57 | - | - | - | -29.1% | 43 | 42 |
Where CARA.ST ranks against its sector peers on each metric.